Foundayo (orforglipron) has made headlines as the first oral GLP-1 receptor agonist approved by the FDA for chronic weight management. But beyond weight loss, many people with type 2 diabetes are asking: Can I use Foundayo for my diabetes? The short answer is — not yet, but the data is incredibly promising. With strong clinical results showing significant A1C reductions and meaningful weight loss, Foundayo could soon become a major player in diabetes care. In this article, we break down everything you need to know about orforglipron's potential for type 2 diabetes, including current approval status, clinical trial results, safety, and how it compares to other diabetes medications.
What Is Foundayo and How Does It Work?
Foundayo (orforglipron) is an oral GLP-1 receptor agonist developed by Eli Lilly. Unlike traditional injectable GLP-1s like Ozempic or Mounjaro, Foundayo comes in pill form — making it a major convenience win for patients who prefer oral medications. It works by mimicking the action of the natural hormone GLP-1 (glucagon-like peptide-1), which plays a key role in regulating blood sugar and appetite.
Specifically, Foundayo helps by:
- Stimulating insulin secretion from the pancreas when blood sugar is high
- Reducing glucagon release, which lowers glucose production in the liver
- Slowing gastric emptying, helping you feel fuller longer
- Reducing appetite and food intake
These mechanisms make Foundayo effective for both weight management and blood sugar control — which is why the diabetes community has been watching closely.
Current FDA Approval Status
As of April 1, 2026, Foundayo received FDA approval for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, or sleep apnea.
However, Foundayo is not yet FDA-approved for the treatment of type 2 diabetes. Eli Lilly has announced that it is actively preparing a separate regulatory submission for a type 2 diabetes indication, based on compelling data from the ATTAIN-2 trial. This strategic move — launching for obesity first — is common in the pharmaceutical world, as the obesity market is larger and offers greater pricing flexibility.
What the Clinical Data Shows for Diabetes
The most important evidence for people with type 2 diabetes comes from the ATTAIN-2 trial, a completed Phase 3 clinical study evaluating orforglipron in adults with uncontrolled type 2 diabetes.
Key findings from the trial:
- At the highest dose, participants experienced an average 1.6% reduction in A1C from baseline
- Participants also achieved approximately 10% reduction in body weight — a significant benefit for those managing both diabetes and obesity
- Improvements in fasting glucose, insulin sensitivity, and lipid profiles were also observed
- Most patients reported good tolerability, with side effects primarily limited to mild gastrointestinal discomfort
These results are particularly impressive for an oral medication. Injectable GLP-1s like Ozempic and Mounjaro typically show A1C reductions of 1.5–2.0% in similar trials. The fact that Foundayo achieves nearly the same level of A1C control with a daily pill — no injections, no fasting requirements — makes it a compelling future option for diabetes patients.
When Will Foundayo Be Approved for Diabetes?
A formal FDA approval for the type 2 diabetes indication is expected in late 2026 or early 2027, based on Lilly's submission timeline. The company chose to launch for obesity first to build market presence, generate real-world data, and establish pricing strategy before pursuing the diabetes label.
This phased approach is not unusual — Novo Nordisk followed a similar playbook with semaglutide, launching Wegovy for weight management and Ozempic for diabetes as separate products. Lilly appears to be pursuing a single brand (Foundayo) with expanded labeling.
Can Your Doctor Prescribe Foundayo Off-Label for Diabetes?
Technically, yes — doctors can prescribe any FDA-approved drug for off-label uses. Since Foundayo is approved for weight management, a physician could prescribe it to a patient with type 2 diabetes, especially if that patient also has obesity or overweight.
However, there are important caveats:
- Insurance coverage is unlikely unless Foundayo carries a formal diabetes label. Most insurers require FDA approval for specific indications before covering a medication.
- Patients would likely need to pay out of pocket, which can be significant for a brand-name GLP-1 medication.
- Some doctors may be hesitant to prescribe off-label due to liability or reimbursement concerns.
If you are considering off-label use, discuss the risks, benefits, and costs with your healthcare provider. For help understanding pricing and savings options, check out our Foundayo Cost and Pricing Guide and Foundayo Savings Card Guide.
How Foundayo Compares to Other Diabetes GLP-1 Medications
Foundayo is entering a well-established field of GLP-1 diabetes treatments. Here is how it stacks up against the current leading options:
Foundayo vs Rybelsus (Oral Semaglutide 14mg)
Rybelsus is the only other oral GLP-1 currently approved for type 2 diabetes. While both offer the convenience of a pill, Foundayo appears to deliver similar or slightly better A1C reduction in trials (roughly 1.6% vs 1.4–1.5%) and more substantial weight loss (approximately 10% vs 6–8%). The biggest practical difference: Rybelsus must be taken on an empty stomach with a small sip of water, then you must wait 30 minutes before eating. Foundayo has no such fasting requirement, making it significantly more convenient for daily use.
Foundayo vs Ozempic (Injectable Semaglutide)
Ozempic is a highly effective injectable GLP-1 that can reduce A1C by up to 2.0% at maximum doses and promote 12–15% weight loss. It is administered once weekly. While Ozempic likely provides stronger glucose control at its highest dose, Foundayo offers a needle-free alternative with good efficacy. For patients who prefer pills over injections, the trade-off in peak efficacy may be worthwhile.
If you are currently on Ozempic and considering the switch, our Switching from Ozempic to Foundayo guide walks through the process step by step.
Foundayo vs Mounjaro (Injectable Tirzepatide)
Mounjaro holds the strongest A1C reduction data in the GLP-1 class, with reductions of up to 2.4% and weight loss exceeding 15% in clinical trials. It is a dual GIP/GLP-1 agonist administered as a once-weekly injection. Foundayo does not match Mounjaro's peak efficacy, but it offers a non-injectable alternative for patients who want to avoid needles and still achieve meaningful improvements in blood sugar and weight.
Foundayo for People with Both Obesity and Type 2 Diabetes
For individuals living with both type 2 diabetes and obesity, Foundayo may be one of the most compelling options available. It is already approved for weight management and shows strong potential for diabetes control — meaning it can address both conditions simultaneously with a single daily pill.
This dual benefit is especially valuable because obesity and type 2 diabetes are closely linked. Losing weight improves insulin sensitivity, reduces systemic inflammation, and lowers A1C. With Foundayo, patients can target both issues with one medication — no need to manage multiple prescriptions or injection schedules.
For more on how oral GLP-1s are changing the weight loss landscape, see our guide: Best Oral GLP-1 for Weight Loss in 2026.
Safety Considerations for Diabetic Patients
Like all GLP-1 receptor agonists, Foundayo can cause gastrointestinal side effects, especially during the first few weeks of treatment. Common side effects include:
- Nausea
- Diarrhea
- Constipation
- Abdominal pain
- Headache
These side effects are usually mild to moderate and tend to improve over time. Most patients adapt within 2–4 weeks. For a week-by-week breakdown of what to expect, read our Foundayo Side Effects Week by Week guide.
Hypoglycemia risk is low when Foundayo is used alone. However, if you take insulin or a sulfonylurea (such as glipizide or glyburide), your risk of low blood sugar increases significantly. Your doctor may need to reduce the dose of these medications when starting Foundayo.
Important safety note: Do not combine Foundayo with other GLP-1 medications. This includes injectable or oral GLP-1s like Ozempic, Mounjaro, or Rybelsus. Combining GLP-1 receptor agonists increases the risk of severe gastrointestinal side effects and is not recommended.
The Bottom Line
Foundayo is not yet FDA-approved for type 2 diabetes, but the clinical evidence is strong and approval is expected in late 2026 or 2027. With a 1.6% A1C reduction and 10% body weight loss in the ATTAIN-2 trial, it is shaping up to be one of the most effective oral options for diabetes management.
If you have type 2 diabetes and are interested in Foundayo, talk to your doctor about your options — including whether off-label use makes sense for your situation. Be prepared that insurance may not cover it without the diabetes label. In the meantime, explore cost-saving strategies through the Foundayo Savings Card and learn more about access in our How to Get Foundayo in 2026 guide.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Foundayo is not currently FDA-approved for the treatment of type 2 diabetes. Individual results may vary based on health status, dosage, and other factors.